Table 1.
Rivastigmine Oral (n = 23) | Rivastigmine Patch (n = 62) | P 1 Value | P 2 Value | |||
---|---|---|---|---|---|---|
Age | 81.7 ± 6.6 | 76.7 ± 8.2 | .010 | |||
Sex (♂/♀) | 11/12 | 29/33 | .931 | |||
Education | 5.5 ± 2.2 | 5.3 ± 1.7 | .845 | |||
Comorbidities, % | ||||||
HT | 60.9 | 62.9 | .863 | |||
CHF | 0 | 4.8 | .560 | |||
AF | 17.4 | 8.1 | .245 | |||
CAD | 26.1 | 19.4 | .555 | |||
Assessment | ||||||
Baseline | 12 mg/d | Baseline | 10 cm2/d | |||
MMSE | 16.3 ± 5.4 | 15.5 ± 4.2 | .565 | |||
IADL | 5.3 ± 4.2 | 5.5 ± 4.7 | .743 | |||
BADL | 80.0 ± 20.2 | 83.3 ± 22.7 | .343 | |||
MNA | 10.5 ± 2.2 | 10.2 ± 3.1 | .553 | |||
Systolic BP, mm Hg | 139.5 ± 18.4 | 138.7 ± 24.2 | 137.0 ± 18.2 | 137.3 ± 19.6 | .693 | .777 |
Diastolic BP, mm Hg | 80.2 ± 10.2 | 79.7 ± 12.9 | 80.0 ± 9.8 | 75.5 ± 8.9 | .962 | .245 |
PP, mm Hg | 58.9 ± 11.6 | 58.9 ± 16.3 | 56.5 ± 13.9 | 61.9 ± 7.0 | .364 | .215 |
ECG Parameters | ||||||
Heart rate | 70.4 ± 13.0 | 72.7 ± 16.6 | 73.8 ± 16.3 | 69.4 ± 12.6 | .595 | .035 |
PR, ms | 178.8 ± 29.0 | 174.1 ± 23.4 | 169.9 ± 30.3 | 171.0 ± 25.6 | .191 | .176 |
QRS, ms | 92.2 ± 18.4 | 92.6 ± 18.0 | 92.3 ± 19.8 | 94.0 ± 18.9 | .976 | .287 |
QT, ms | 396.5 ± 42.7 | 395.0 ± 45.6 | 390.8 ± 45.9 | 400.9 ± 39.8 | .498 | .111 |
QTc, ms | 425.0 ± 27.4 | 428.0 ± 42.2 | 424.1 ± 32.5 | 423.6 ± 39.3 | .696 | .928 |
QTc > 450 ms, n | 5 | 2 | 13 | 16 | .558 | .976 |
Abbreviations: AF, atrial fibrillation; BADL, Basic activity of daily living (0 [worst]-100 [best]); BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; ECG, electrocardiogram; HT, hypertension; IADL, Instrumental activity of daily living (0 [worst]-17 [best]); MMSE, Mini-Mental State Examination(0 [worst]-30 [best]); MNA, Mini Nutritional Assessment(0 [worst]-14 [best]; PP, Pulse Pressure.
a P 1 value for baseline and P 2 value for second comparisons.